Revisiting the hyperhemolysis paradigm

Blood

Volumn 126, Issue 6, 2015, Pages 695-696

  Gladwin, Mark T ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ARGINASE 1; HAPTOGLOBIN; HEMOGLOBIN; HEMOPEXIN; NITRIC OXIDE; OXIDOREDUCTASE; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR 4; AMINE OXIDE; HYDROXYUREA; IMIDAZOLE DERIVATIVE; SCAVENGER;

BLOOD VESSEL FUNCTION; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HUMAN; HYPERHEMOLYSIS; LEUKOCYTE ADHERENCE; LEUKOCYTE ROLLING; NOTE; OXIDATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY ARTERY; PULMONARY HYPERTENSION; SICKLE CELL ANEMIA; SYSTOLIC BLOOD PRESSURE; ANIMAL; BLOOD TRANSFUSION; BRACHIAL ARTERY; DRUG EFFECTS; FEMALE; LEUKOCYTE; LUNG; MALE; METABOLISM; PATHOPHYSIOLOGY; TRICUSPID VALVE REGURGITATION;

ANEMIA, SICKLE CELL; ANIMALS; BLOOD TRANSFUSION; BRACHIAL ARTERY; CYCLIC N-OXIDES; FEMALE; FREE RADICAL SCAVENGERS; HEMOGLOBINS; HUMANS; HYDROXYUREA; HYPERTENSION, PULMONARY; IMIDAZOLES; LEUKOCYTES; LUNG; MALE; NITRIC OXIDE; TRICUSPID VALVE INSUFFICIENCY;

EID: 84940063249     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-06-649491     Document Type: Note

References (13)

1. Detterich JA, Kato RM, Rabai M, Meiselman HJ, Coates TD, Wood JC. Chronic transfusion therapy improves but does not normalize systemic and pulmonary vasculopathy in sickle cell disease. Blood. 2015;126(6):703-710.
2. Almeida CB, Souza LEB, Leonardo FC, et al. Acute hemolytic vascular inflammatory processes are prevented by nitric oxide replacement or a single dose of hydroxyurea. Blood. 2015;126(6):711-720.
3. Gladwin MT, Schechter AN, Ognibene FP, et al. Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation. 2003;107(2):271-278.
4. Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med. 2002;8(12):1383-1389.
5. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA. 2005;293(13):1653-1662.
6. Gladwin MT, Shelhamer JH, Ognibene FP, et al. Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. Br J Haematol. 2002;116(2):436-444.
7. Morris CR, Kato GJ, Poljakovic M, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA. 2005;294(1):81-90.
8. Ghosh S, Adisa OA, Chappa P, et al. Extracellular hemin crisis triggers acute chest syndrome in sickle mice. J Clin Invest. 2013;123(11):4809-4820.
9. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350(9):886-895.
10. Mehari A, Gladwin MT, Tian X, Machado RF, Kato GJ. Mortality in adults with sickle cell disease and pulmonary hypertension. JAMA. 2012;307(12):1254-1256.
11. Bunn HF, Nathan DG, Dover GJ, et al. Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood. 2010;116(5):687-692.
12. Caughey MC, Poole C, Ataga KI, Hinderliter AL. Estimated pulmonary artery systolic pressure and sickle cell disease: a meta-analysis and systematic review. Br J Haematol. 2015;170(3):416-424.
13. Klings ES, Machado RF, Barst RJ, et al American Thoracic Society Ad Hoc Committee on Pulmonary Hypertension of Sickle Cell Disease. An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med. 2014;189(6):727-740.